Owing to the high prevalence of prostate cancer, tumour marker research still is particularly challenging as PSA is known to have some limitations in its application especially in the diagnostic window of 4–10 ng ml−1 (Partin et al, 1990). This evidence concerns the gene KLK3 and neoplasm.